Lanreotide Peptide: Somatuline Depot Uses, Evidence and Safety Limits
Lanreotide peptide guide covering somatostatin analog biology, Somatuline Depot labels, acromegaly and GEP-NET evidence, half-life and safety limits.
Lanreotide is a peptide drug with a very different evidence profile from the research-market peptides sold online. It is a synthetic cyclic octapeptide analog of natural somatostatin, marketed as the long-acting depot products Somatuline Depot in the United States and Somatuline Autogel in many other countries. It is a prescription medicine developed by Ipsen, with an initial US FDA approval in 2007.
The key idea is that lanreotide imitates somatostatin, the body's broad "off switch" hormone. By doing so over weeks at a time from a single deep subcutaneous depot, it lowers growth hormone, IGF-1 and several gut hormones. That makes it a treatment for specific endocrine and oncologic conditions, not a general wellness or performance peptide.
This guide is educational and not medical advice. Lanreotide is a prescription medicine that should be started, monitored, adjusted or stopped only through qualified medical care.
For related context, compare this guide with octreotide, the other major somatostatin analog, and with gut-acting peptides such as linaclotide and teduglutide. You can also review what peptides are and the peptide half-life guide for background.
Lanreotide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic cyclic octapeptide analog of somatostatin, sold as Somatuline Depot and Somatuline Autogel. |
| Who makes it? | Ipsen, with initial US FDA approval in 2007. |
| Main targets | High affinity for somatostatin receptors SSTR2 and SSTR5, lower affinity for SSTR1, 3 and 4. |
| Main effect | Suppression of growth hormone, IGF-1 and various gut and neuroendocrine hormones. |
| Approved uses | Acromegaly, unresectable GEP-NETs to improve progression-free survival, and carcinoid syndrome. |
| Route | Deep subcutaneous injection, once every 4 weeks. |
| Evidence type | FDA label, pharmacology studies and randomized trials such as CLARINET. |
How A Somatostatin Analog Works
Natural somatostatin is a short-lived hormone that inhibits a wide range of endocrine, neuroendocrine, exocrine and paracrine functions. It dampens growth hormone release from the pituitary, reduces several gut hormones, and slows some secretory and proliferative signals. The problem with native somatostatin as a drug is that it is cleared within minutes, which makes practical dosing impossible.
Lanreotide solves that by being a stable analog. According to the FDA prescribing information, lanreotide has high affinity for human somatostatin receptors 2 and 5 (SSTR2 and SSTR5) and reduced affinity for SSTR1, 3 and 4. Activity at SSTR2 and SSTR5 is the primary mechanism believed responsible for growth hormone inhibition. These receptors are concentrated in the pituitary, the pancreas and many neuroendocrine tumors, which is why the same molecule is useful across acromegaly and neuroendocrine cancer.
The depot formulation is the second half of the story. Lanreotide is formulated as a supersaturated aqueous gel that releases slowly after a deep subcutaneous injection. The FDA label notes that plasma growth hormone falls rapidly after a single injection and stays suppressed for at least 28 days, enabling a once-monthly schedule. This slow-release behavior dominates its pharmacokinetics: the apparent terminal elimination of the depot is measured in weeks, on the order of about 23 to 30 days, because absorption from the depot, not true metabolic clearance, controls how long the drug persists. The deeper mechanics of this "flip-flop" behavior are covered in the peptide half-life guide.
Approved Uses And Evidence
Lanreotide is unusual among peptides discussed online because it has real, label-backed indications and randomized evidence behind them. The FDA approval covers three areas.
| Indication | What the label and trials support | Important limit |
|---|---|---|
| Acromegaly | Long-term treatment in patients with inadequate response to, or ineligibility for, surgery and radiotherapy, lowering GH and IGF-1. | It controls hormone levels but does not replace surgery in all patients, and response is monitored by GH and IGF-1. |
| GEP-NETs | Unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival. | The benefit is delayed progression, not proven cure, and it applies to specific tumor grades. |
| Carcinoid syndrome | Treatment of carcinoid syndrome, where it reduces the need for short-acting somatostatin analog rescue therapy. | It manages hormone-driven symptoms; it is not a standalone tumor cure. |
In acromegaly, the pharmacodynamic case is direct. The label states that lanreotide reduces growth hormone in a dose-dependent way and can normalize GH and IGF-1 in many patients. Registry data such as the SODA registry have described real-world use of the extended-release aqueous-gel formulation in acromegaly patients in the United States.
In neuroendocrine tumors, the central evidence is the phase 3 CLARINET trial, published in the New England Journal of Medicine in 2014. In 204 patients with metastatic enteropancreatic neuroendocrine tumors, lanreotide 120 mg every 28 days significantly prolonged progression-free survival compared with placebo, with median progression-free survival not reached in the lanreotide group versus 18.0 months with placebo. A later open-label extension reported on longer-term outcomes. For carcinoid syndrome, a placebo-controlled study supported reduced use of short-acting somatostatin rescue therapy and reduced urinary 5-HIAA, a marker of serotonin metabolism.
This is a genuinely strong evidence base. The honest limit is that it is specific. CLARINET studied particular tumor types and grades, the acromegaly data concern hormone control rather than tumor cure of the pituitary, and none of this supports lanreotide as a general "longevity" or metabolic optimization peptide.
Reference Dosing, Not A Recommendation
The figures below come from the FDA label and are presented for understanding only. They are not dosing advice, and lanreotide is administered and titrated by clinicians.
For acromegaly, the label describes a typical starting dose of 90 mg by deep subcutaneous injection every 4 weeks for 3 months, then adjustment within a roughly 60 to 120 mg range every 4 weeks based on GH and IGF-1 response. For GEP-NETs and for carcinoid syndrome, the labeled dose is 120 mg every 4 weeks. The product is supplied as 60 mg, 90 mg and 120 mg single-dose prefilled syringes given as a deep subcutaneous injection, typically in the upper outer buttock.
The route matters. Unlike many self-administered research peptides, this is a viscous depot delivered deep subcutaneously, historically by a healthcare professional, though some patients or partners are trained to administer the aqueous-gel formulation. The schedule is monthly, not daily, because the whole point of the formulation is slow release.
Safety Limits
Lanreotide safety follows directly from suppressing somatostatin-controlled pathways across the body. Because it dampens many secretory functions, its side effects span the gallbladder, glucose control, heart rate and thyroid.
| Safety issue | Why it matters |
|---|---|
| Gallstones and biliary effects | Cholelithiasis is common because somatostatin analogs reduce gallbladder motility; the label reports gallstones in a meaningful share of patients. |
| Gastrointestinal effects | Diarrhea, abdominal pain, nausea, constipation and flatulence are among the most frequent adverse reactions. |
| Blood sugar changes | Lanreotide can cause both hyperglycemia and hypoglycemia, so glucose monitoring is advised, especially in diabetes. |
| Slow heart rate | Sinus bradycardia and other bradycardia have been reported; caution applies with drugs that slow the heart. |
| Reduced thyroid function | Slight decreases in thyroid function have been seen during treatment in acromegalic patients. |
| Injection-site reactions | Pain, nodules or reactions at the deep subcutaneous injection site can occur. |
The most commonly reported adverse reactions in acromegaly trials were gastrointestinal disorders, cholelithiasis and injection-site reactions, with diarrhea and cholelithiasis among the most frequent. These are manageable in a monitored clinical setting, but they reinforce that lanreotide is a real drug with systemic effects, not a benign supplement.
How To Evaluate A Lanreotide Claim
Because lanreotide is a legitimate peptide medicine, online sources sometimes borrow its credibility to sell unrelated products. Ask a few questions before trusting a claim.
First, which formulation and indication is being discussed: acromegaly, GEP-NETs or carcinoid syndrome? These are different patient populations with different goals.
Second, is the source citing the FDA label or a randomized trial such as CLARINET, or is it citing a vendor page? Only the former is evidence.
Third, does the source acknowledge gallstone, glucose, heart-rate and thyroid monitoring? A source that omits safety is incomplete.
Fourth, is the claim implying that a clinic-administered monthly oncology and endocrinology depot is something to buy and self-inject for general wellness? That is a red flag.
Lanreotide Versus Octreotide
Lanreotide is most directly comparable to octreotide, the other major somatostatin analog. Both bind preferentially to SSTR2 and SSTR5 and are used in acromegaly and neuroendocrine tumors. The practical differences are largely formulation and pharmacokinetics. Octreotide exists as a short-acting subcutaneous form and a long-acting intramuscular depot, while lanreotide Autogel is a deep subcutaneous prefilled gel designed for once- monthly dosing. Choice between them is a clinical decision based on the specific condition, response, tolerability and practical administration.
Other peptides in this educational cluster, such as linaclotide for gut signaling, teduglutide for intestinal adaptation, icatibant for hereditary angioedema and oxytocin, act through entirely different receptor systems. They share only the broad fact of being approved peptide drugs with specific, monitored uses rather than open-ended optimization tools.
Bottom Line
Lanreotide is a real, FDA-approved peptide medicine and one of the better- evidenced compounds in this category. As a long-acting somatostatin analog, it suppresses growth hormone and IGF-1 in acromegaly, and the phase 3 CLARINET trial showed it can prolong progression-free survival in gastroenteropancreatic neuroendocrine tumors. It also helps control carcinoid syndrome.
The same mechanism sets its limits. Lanreotide affects the gallbladder, glucose control, heart rate and thyroid, and it is delivered as a monthly deep subcutaneous depot under medical supervision. It is a treatment for defined endocrine and oncologic conditions, not a general wellness peptide, and any claim that frames it otherwise should be treated with skepticism.
References
DailyMed. Somatuline Depot (lanreotide acetate) prescribing information.
US FDA. Somatuline Depot (lanreotide) injection, full prescribing information.
US FDA. Somatuline Depot (lanreotide) original 2007 approval label.
Caplin ME, et al. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors (CLARINET), New England Journal of Medicine, 2014.
Caplin ME, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
ClinicalTrials.gov. Efficacy and Safety Study of Somatuline Depot (lanreotide) Injection to Treat Carcinoid Syndrome (ELECT).
Wolin EM, et al. Lanreotide extended-release aqueous-gel formulation in patients with acromegaly in the United States: 1-year data from the SODA registry.
Günther T, et al. Structural insights into the binding modes of lanreotide and pasireotide with somatostatin receptors.
National Center for Biotechnology Information. PubChem compound summary: Lanreotide.